Do you want to read an article? Please log in or register.
Composite endpoints in COPD: clinically important deterioration in the UPLIFT trial
COPD
RECOMMENDED
Related content
RECOMMENDED
COPD
Preventing Clinically Important Deterioration of COPD with Addition of Umeclidinium to Inhaled Corticosteroid/Long-Acting β2-Agonist Therapy: An Integrated Post Hoc Analysis
Adv Ther.
Naya IP, Tombs L, Lipson DA, Compton C
doi: 10.1007/s12325-018-0771-4.
COPD
The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD
Int J Chron Obstruct Pulmon Dis.
Anzueto AR, Vogelmeier CF, Kostikas K, Mezzi K, Fucile S, Bader G, Shen S, Banerji D, Fogel R
doi: 10.2147/COPD.S133307.
RECOMMENDED
COPD
Measuring disease activity in COPD: is clinically important deterioration the answer?
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Respir Res.
Singh D, Criner GJ, Naya I, Jones PW, Tombs L, Lipson DA, Han MK
doi: 10.1186/s12931-020-01387-z.
RECOMMENDED
COPD
Effect of a Pulmonary Embolism Diagnostic Strategy on Clinical Outcomes in Patients Hospitalized for COPD Exacerbation: A Randomized Clinical Trial
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
JAMA
Jiménez D, Agustí A, Tabernero E, Jara-Palomares L, Hernando A, Ruiz-Artacho P, Pérez-Peñate G, Rivas-Guerrero A, Rodríguez-Nieto MJ, Ballaz A, Agüero R, Jiménez S, Calle-Rubio M, López-Reyes R, Marcos-Rodríguez P, Barrios D, Rodríguez C, Muriel A, Bertoletti L, Couturaud F, Huisman M, Lobo JL, Yusen RD, Bikdeli B, Monreal M, Otero R, SLICE Trial Group.
doi: 10.1001/jama.2021.14846
Asthma
A novel endpoint for exacerbations in asthma to accelerate clinical development: a post-hoc analysis of randomised controlled trials
Urol Oncol.
Fuhlbrigge AL, Bengtsson T,
Peterson S, Jauhiainen A, Eriksson G, Da Silva CA, Johnson A, Sethi T, Locantore N, Tal-Singer R, Fagerås M
doi: 10.1016/j.urolonc.2017.04.010.
COPD
Effect of ELOM-080 on exacerbations and symptoms in COPD patients with a chronic bronchitis phenotype - a post-hoc analysis of a randomized, double-blind, placebo-controlled clinical trial.
Int J Chron Obstruct Pulmon Dis.
Beeh KM, Beier J, Candler H, Wittig T
doi: 10.2147/COPD.S11765
RECOMMENDED
COPD
Blood eosinophils as a biomarker of future COPD exacerbation risk: pooled data from 11 clinical trials
★ 3
Recommended by
Dr Martin Frey, Faculty Member
Respir Res.
Singh D, Wedzicha JA, Siddiqui S, de la Hoz A, Xue W, Magnussen H, Miravitlles M, Chalmers JD, Calverley PMA
doi: 10.1186/s12931-020-01482-1.
RECOMMENDED
COPD
Effect of Theophylline as Adjunct to Inhaled Corticosteroids on Exacerbations in Patients With COPD: A Randomized Clinical Trial
JAMA.
Devereux G, Cotton S, Fielding S, McMeekin N, Barnes PJ, Briggs A, Burns G, Chaudhuri R, Chrystyn H, Davies L, De Soyza A, Gompertz S, Haughney J, Innes K, Kaniewska J, Lee A, Morice A, Norrie J, Sullivan A, Wilson A, Price D
doi: 10.1001/jama.2018.14432.
RECOMMENDED
COPD
Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Respir Res.
Maltais F, Bjermer L, Kerwin EM, Jones PW, Watkins ML, Tombs L, Naya IP, Boucot IH, Lipson DA, Compton C, Vahdati-Bolouri M, Vogelmeier CF
doi: 10.1186/s12931-019-1193-9.